SOURCE: Skystar Bio-Pharmaceuticals

Skystar Bio-Pharmaceuticals

November 05, 2014 14:31 ET

Skystar Bio-Pharma Featured on Wide World of Stocks Television

Interview With Mr. Scott Cramer Highlighting Growth Trends of China's Animal Pharma Space

XI'AN, CHINA--(Marketwired - Nov 5, 2014) -  Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that the interview of Mr. Scott Cramer, Director, Corporate Development and U.S. Representative for Skystar, on Wide World of Stocks will broadcast today, Wednesday, November 5, 2014 into more than 50 million homes nationwide over BizTV, BizTV Radio, and You Tube America Networks.

In the interview, Mr. Cramer highlighted the Company's recent increased manufacturing capacity, potential future revenue growth and how demand for Skystar's products are being driven by population growth, stricter GMP manufacturing regulations instituted by the Ministry of Agriculture as well as increases in meat and dairy consumption driven by China's emerging middle class.

"It was a pleasure to present Skystar's compelling investment proposition as the only U.S listed company in China's growing animal pharmaceutical space to the viewers of Wide World of Stocks," said Mr. Cramer.

WWOS' interview with Skystar Bio Pharmaceutical Company can be seen nationwide today on BizTv at 5:00pm EST and on Youtoo America (formally America One Network) at 6:00pm EST.

Find Us in your Market
Wide World of Stocks YouTube

About Skystar Bio-Pharmaceutical Company

Skystar is a China-based developer, manufacturer and distributor of veterinary healthcare and medical care products. Skystar has four product lines: veterinary medicines, probiotics, vaccines and feed additives formulated and packaged in house across several modern manufacturing and distributions facilities. Skystar's distribution network includes almost 3,000 distribution agents of which 360 are franchised stores with exclusivity agreements covering 29 provinces throughout China. For additional information, please visit

Safe Harbor Statements

When used in this release, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, without limitation, the Company's ability to complete the launch of its IgG kits in the anticipated timeframe and to attain the anticipated revenue and market penetration, as well as other related efforts at the Huxian facilities, the Company's ability to timely, effectively and accurately assess the efficacy and commercial potential of any technologies that may results from such R&D efforts, the Company's ability to timely and effectively commercialize any such technologies. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

About Wide World of Stocks

Wide World of Stocks delivers visibility to companies in the small-cap sector. Wide World of Stocks offers a complete multi-level awareness package that provides valuable exposure for your company, products and services. Wide World of Stocks is a print and digital content provider with multi-channel integration including television, webcasts, podcasts and a magazine in both digital and print formats. WWOS has been seen in 100+ million homes, regionally and nationally on cable and major networks including CBS, NBC, ABC, and FOX. For more information visit Wide World of Stocks is owned and published by Valhalla Venture Group, LLC. Learn more at

Contact Information

  • Contact:
    Skystar Bio-Pharmaceutical Company
    Scott Cramer
    Director -- Corporate Development & U.S. Representative
    (407) 645-4433

    Christopher Chu
    (212) 889-4350
    Email Contact